Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Statins—Almost 30 Years of Use in the United States and Still Not Quite There

Statins—Almost 30 Years of Use in the United States and Still Not Quite There Research Original Investigation US National Trends in US Statin Use and Expenditures Editor's Note Statins—Almost 30 Years of Use in the United States and Still Not Quite There Robert A. Harrington, MD The first statin, lovastatin, was approved for commercial use garner adverse effects that lessen their personal gains. It is not in the United States almost 30 years ago on September 1, 1987. hard to see this as a balance of broad public health benefit Since that time, tens of millions of individuals have been against individual risks. treated with statins as therapy for the secondary and primary A recent review summarizing several decades of random- prevention of coronary atherosclerotic events, including car- ized clinical trials of statin therapy concluded that lowering low- diac death and myocardial infarction. Without question, wide- density lipoprotein cholesterol level with statins is associ- spread application of statin therapy has been a major public ated with a predictable and reliable reduction of vascular health advance, especially when used in high doses for pa- events; because of the linear relationship between choles- tients at highest cardiac risk. terol levels and outcomes, the authors noted that risk is espe- The 2013 American College of Cardiology/American http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Statins—Almost 30 Years of Use in the United States and Still Not Quite There

JAMA Cardiology , Volume 2 (1) – Jan 14, 2017

Statins—Almost 30 Years of Use in the United States and Still Not Quite There

Abstract

Research Original Investigation US National Trends in US Statin Use and Expenditures Editor's Note Statins—Almost 30 Years of Use in the United States and Still Not Quite There Robert A. Harrington, MD The first statin, lovastatin, was approved for commercial use garner adverse effects that lessen their personal gains. It is not in the United States almost 30 years ago on September 1, 1987. hard to see this as a balance of broad public health benefit Since that time, tens of...
Loading next page...
 
/lp/american-medical-association/statins-almost-30-years-of-use-in-the-united-states-and-still-not-zHUfHXT0zq
Publisher
American Medical Association
Copyright
Copyright 2016 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2016.4709
Publisher site
See Article on Publisher Site

Abstract

Research Original Investigation US National Trends in US Statin Use and Expenditures Editor's Note Statins—Almost 30 Years of Use in the United States and Still Not Quite There Robert A. Harrington, MD The first statin, lovastatin, was approved for commercial use garner adverse effects that lessen their personal gains. It is not in the United States almost 30 years ago on September 1, 1987. hard to see this as a balance of broad public health benefit Since that time, tens of millions of individuals have been against individual risks. treated with statins as therapy for the secondary and primary A recent review summarizing several decades of random- prevention of coronary atherosclerotic events, including car- ized clinical trials of statin therapy concluded that lowering low- diac death and myocardial infarction. Without question, wide- density lipoprotein cholesterol level with statins is associ- spread application of statin therapy has been a major public ated with a predictable and reliable reduction of vascular health advance, especially when used in high doses for pa- events; because of the linear relationship between choles- tients at highest cardiac risk. terol levels and outcomes, the authors noted that risk is espe- The 2013 American College of Cardiology/American

Journal

JAMA CardiologyAmerican Medical Association

Published: Jan 14, 2017

References